Background: The Bromodomain Adjacent to the Zinc Finger Domain 1B (BAZ1B) is a versatile nuclear protein. BAZ1B acts on chromatin remodeling, participates in DNA replication and damage repair, and is involved in RNA transcription based on its kinase activity. Although many experimental data support a close relationship between BAZ1B and cancer, its role in pan-cancer remains unclear. Our study aimed to analyze the prognostic and immune functions of BAZ1B expression in different cancers.

Methods: Based on different databases, we investigated the potential carcinogenicity of BAZ1B, including the expression of all TCGA tumors, correlation with prognosis, Tumor Microenvironment (TME), protein phosphorylation, and functional enrichment.

Results: The results showed that BAZ1B was overexpressed in a variety of cancers, and there was a significant correlation between gene mutations and poor prognosis associated with high expression in most cancer patients. We observed elevated phosphorylation levels in breast cancer and lung adenocarcinoma. A significant relationship was also found between BAZ1B expression and TME, including tumor-associated fibroblast infiltration. We also observed that the cellular function of DNA and hepatocellular carcinoma may be related to the molecular mechanism of BAZ1B.

Conclusion: The prognostic and immunological markers of BAZ1B provides a new understanding for future studies in our first pan-cancer analysis.